Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability

Antibodies directed to tumour necrosis factor-α (TNF-α) are very effective in treating paediatric Crohn’s disease (CD). Over the last few years, research has provided important new insights into how to optimise this treatment’s effectiveness. Research on predictors for anti-TNF treatment responsiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Cozijnsen, M. A., Samsom, J. N., de Ridder, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Leading Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775976/
https://www.ncbi.nlm.nih.gov/pubmed/29079905
http://dx.doi.org/10.1007/s40272-017-0266-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775976/
https://www.ncbi.nlm.nih.gov/pubmed/29079905
http://dx.doi.org/10.1007/s40272-017-0266-9

Ejemplares similares